Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/02/2022* -- Results Q3 2022 -- -0.06 --
11/02/2022* 16:30 EST Earnings Call Q3 2022 -- -- --
08/04/2022 -- Results Q2 2022 0.04 0.02 84.59%
08/04/2022 16:30 EST Earnings Call Q2 2022 -- -- --
05/05/2022 -- Results Q1 2022 -0.03 -0.09 65.57%
05/05/2022 16:30 EST Earnings Call Q1 2022 -- -- --
02/24/2022 -- Results Q4 2021 -0.02 -0.06 64.10%
02/24/2022 16:30 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 11/02/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/04/2022
Beat/Miss Upgrade
Return Since -30.36%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 35-gene panel with the capability to identify the elevated risk of developing eight types of cancer. Other diagnostic products include BRACAnalysisCDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; Prequel, with is a noninvasive prenatal test; and Prolaris, which identifies prostate cancer patients that can pursue active surveillance. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
URL https://www.myriad.com
Investor Relations URL https://investor.myriad.com/
HQ State/Province Utah
Sector Healthcare
Industry Diagnostics & Research
Equity Style Small Cap/Blend
Next Earnings Release Nov. 02, 2022 (est.)
Last Earnings Release Aug. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
26.72%
-61.38%
106.0%
-15.36%
-6.33%
-27.38%
39.57%
-30.87%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-23.87%
--
--
--
--
--
--
158.8%
-51.01%
44.69%
3.70%
6.56%
-3.86%
27.03%
39.49%
5.12%
-15.73%
39.17%
17.30%
14.61%
42.56%
27.96%
-20.50%
18.16%
-8.83%
-29.63%
-52.07%
-43.76%
-71.37%
-38.63%
70.63%
-53.49%
-74.70%
As of September 30, 2022.

Profile

Edit
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 35-gene panel with the capability to identify the elevated risk of developing eight types of cancer. Other diagnostic products include BRACAnalysisCDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; Prequel, with is a noninvasive prenatal test; and Prolaris, which identifies prostate cancer patients that can pursue active surveillance. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
URL https://www.myriad.com
Investor Relations URL https://investor.myriad.com/
HQ State/Province Utah
Sector Healthcare
Industry Diagnostics & Research
Equity Style Small Cap/Blend
Next Earnings Release Nov. 02, 2022 (est.)
Last Earnings Release Aug. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
PSYK 96592.00 USD 6.41%
GNOM 6.897M USD 3.29%
PSCH 4.821M USD 1.53%
PMJPX 3.985M USD 0.98%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter MYGN Tweets